CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis. The Italian generic drug and API maker said Tuesday that it is buying an API ...

Dublin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients Industry in India (2025 - 2030)" report has been added to ResearchAndMarkets.com's offering. In 2023, the active ...

India is the largest provider of generic drugs globally. Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 ...

ANKLESHWAR, India--(BUSINESS WIRE)--RUSAN PHARMA PRIVATE LIMITED, a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that ...

The global market for active pharmaceutical ingredients (APIs) in 2013 was estimated at US$ 119.7 billion and is projected to grow at a CAGR of 6.5% to a value of US$ 185.9 billion by 2020 The Asian ...

The Indian Active Pharmaceutical Ingredients (API) market in 2025 was valued at US$14.2 billion and is expected to grow at a CAGR of 8.5% to reach US$21.46 billion by 2030. In contrast, the global ...

Indian drugmaker Mankind Pharma intends to add an active pharmaceutical ingredient (API) manufacturing facility to its network of 16 production plants in India. The company says it will invest about ...

(MENAFN- GlobeNewsWire - Nasdaq) The Indian Active Pharmaceutical Ingredients (API) market, valued at INR 1.07 trillion in 2023, is set to reach INR 1.82 trillion by 2030, growing at a CAGR of ~8.26%.